Beyond Air to Initiate Clinical Study Evaluating High Concentration Nitric Oxide for the Treatment of COVID-19 Patients in the United States
Beyond Air, Inc. (XAIR)
Company Research
Source: GlobeNewswire
Food and Drug Administration (FDA) agrees to a trial using the LungFit™ system to treat COVID-19 patients Applications pending with Health Canada and the Israel Ministry of Health to allow studies to be conducted using high concentration nitric oxide to treat COVID-19 patients GARDEN CITY, N.Y., April 16, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) agreed with the initiation of a clinical study in the U.S. using its LungFitTM system to treat COVID-19 patients. Applications for funding are pending with the Biomedical Advance Research and Development Authority (BARDA), a division of Health and Human Services (HHS). “We are plea
Show less
Read more
Impact Snapshot
Event Time:
XAIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XAIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XAIR alerts
High impacting Beyond Air, Inc. news events
Weekly update
A roundup of the hottest topics
XAIR
News
- Beyond Air, Inc. (NASDAQ: XAIR) had its price target lowered by analysts at Truist Financial Co. from $10.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and WarrantsGlobeNewswire
- Diabetic Foot Ulcers Market to Witness Upsurge Growth by 2032, Estimates DelveInsight | Leading Companies - Anterogen Co., Lavior Pharma, Vitruvian Medical Devices, Oneness Biotech Co., Energenesis Biomedical Co. [Yahoo! Finance]Yahoo! Finance
- Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
XAIR
Earnings
- 2/12/24 - Beat
XAIR
Sec Filings
- 3/22/24 - Form 8-K
- 3/22/24 - Form 424B5
- 3/21/24 - Form 4
- XAIR's page on the SEC website